Stock listing
NASDAQ:NVCT Nuvectis Pharma, Inc. Stock
Home listing (NASDAQ) of Nuvectis Pharma, Inc.
Follow Nuvectis Pharma, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:NVCT
$19.18 USD +0.70 (+3.8%)
Close on Nov 2, 2026
- Day range
- $18.10 – $19.40 USDNov 2, 2026
- Volume
- 213,587 sharesNov 2, 2026
- Market cap
- $626.1M USDAt the close on Nov 2, 2026 · price × 32.64M shares outstanding
- 52-week range
- $5.55 – $29.28 USDLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
- Traded on an average day
- $4.26M USDMedian day 176,900 shares · last 3 months, Aug 3, 2026 – Nov 2, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NVCT · Home | $19.18 USD | +0.70 (+3.8%) | 213,587 | $18.61 | $19.40 | $18.10 | $18.48 | Close on Nov 2, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 2, 2026 · NASDAQ:NVCT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $19.18 | +0.70 | +3.8% | $18.61 | $19.40 | $18.10 | 213,587 | |
| $18.48 | -0.09 | -0.5% | $18.46 | $18.92 | $18.20 | 168,802 | |
| $18.57 | +0.21 | +1.1% | $18.61 | $18.97 | $18.32 | 117,684 | |
| $18.36 | -0.08 | -0.4% | $18.30 | $18.83 | $17.91 | 192,736 | |
| $18.44 | -0.05 | -0.3% | $18.56 | $18.74 | $18.08 | 144,623 | |
| $18.49 | -1.56 | -7.8% | $20.00 | $20.41 | $17.69 | 318,829 | |
| $20.05 | -0.84 | -4.0% | $20.86 | $20.86 | $19.83 | 107,900 | |
| $20.89 | +0.19 | +0.9% | $20.55 | $21.26 | $20.40 | 110,100 | |
| $20.70 | +0.11 | +0.5% | $20.63 | $21.72 | $19.94 | 203,600 | |
| $20.59 | +1.65 | +8.7% | $19.09 | $20.91 | $17.85 | 148,800 | |
| $18.94 | +0.34 | +1.8% | $18.81 | $19.20 | $18.42 | 198,200 | |
| $18.60 | -0.33 | -1.7% | $18.89 | $18.89 | $17.81 | 158,500 | |
| $18.93 | +0.93 | +5.2% | $18.30 | $19.59 | $18.30 | 156,900 | |
| $18.00 | -0.15 | -0.8% | $18.27 | $18.72 | $17.68 | 184,200 | |
| $18.15 | -1.54 | -7.8% | $19.59 | $19.88 | $18.01 | 215,800 | |
| $19.69 | -1.43 | -6.8% | $21.12 | $21.19 | $19.55 | 145,800 | |
| $21.12 | +0.99 | +4.9% | $20.11 | $21.29 | $19.88 | 153,000 | |
| $20.13 | -0.16 | -0.8% | $20.05 | $20.42 | $19.60 | 179,400 | |
| $20.29 | +0.26 | +1.3% | $19.67 | $20.72 | $19.67 | 121,100 | |
| $20.03 | -1.36 | -6.4% | $21.54 | $21.54 | $19.79 | 188,100 | |
| $21.39 | -0.53 | -2.4% | $22.00 | $22.24 | $20.29 | 194,300 | |
| $21.92 | +1.20 | +5.8% | $21.11 | $22.00 | $21.04 | 207,500 | |
| $20.72 | -0.40 | -1.9% | $21.33 | $21.90 | $20.53 | 168,300 | |
| $21.12 | +0.59 | +2.9% | $20.73 | $21.62 | $20.41 | 240,300 | |
| $20.53 | -0.28 | -1.3% | $20.91 | $21.40 | $20.11 | 160,000 | |
| $20.81 | +0.59 | +2.9% | $20.00 | $21.24 | $19.55 | 137,900 | |
| $20.22 | -1.41 | -6.5% | $21.81 | $21.95 | $20.22 | 191,800 | |
| $21.63 | +0.56 | +2.7% | $21.38 | $21.99 | $20.65 | 258,200 | |
| $21.07 | -1.93 | -8.4% | $23.00 | $23.00 | $20.94 | 169,200 | |
| $23.00 | +1.02 | +4.6% | $22.26 | $23.18 | $21.79 | 124,000 | |
| $21.98 | -0.02 | -0.1% | $22.02 | $22.39 | $21.40 | 166,400 | |
| $22.00 | +0.62 | +2.9% | $21.27 | $23.00 | $21.06 | 880,100 | |
| $21.38 | -0.49 | -2.2% | $22.31 | $22.31 | $20.00 | 240,900 | |
| $21.87 | -0.05 | -0.2% | $21.84 | $22.41 | $21.31 | 136,400 | |
| $21.92 | -1.43 | -6.1% | $23.00 | $23.01 | $21.78 | 166,100 | |
| $23.35 | -0.64 | -2.7% | $23.25 | $24.12 | $22.79 | 203,400 | |
| $23.99 | +1.50 | +6.7% | $22.96 | $24.24 | $22.28 | 221,100 | |
| $22.49 | -0.29 | -1.3% | $22.09 | $23.02 | $22.01 | 107,000 | |
| $22.78 | -1.21 | -5.0% | $23.89 | $24.54 | $22.67 | 165,600 | |
| $23.99 | -0.50 | -2.0% | $24.00 | $24.69 | $22.73 | 136,300 | |
| $24.49 | +0.12 | +0.5% | $24.00 | $25.19 | $23.96 | 117,200 | |
| $24.37 | +0.45 | +1.9% | $24.00 | $24.62 | $22.82 | 136,000 | |
| $23.92 | +0.86 | +3.7% | $23.06 | $24.01 | $23.06 | 188,500 | |
| $23.06 | +0.33 | +1.5% | $22.80 | $23.81 | $22.77 | 176,900 | |
| $22.73 | -1.00 | -4.2% | $23.52 | $24.35 | $22.57 | 192,600 | |
| $23.73 | -1.46 | -5.8% | $24.93 | $25.65 | $23.29 | 137,200 | |
| $25.19 | +0.19 | +0.8% | $25.03 | $25.84 | $24.35 | 319,800 | |
| $25.00 | -0.89 | -3.4% | $25.80 | $25.80 | $23.84 | 362,900 | |
| $25.89 | +2.02 | +8.5% | $23.90 | $25.94 | $23.85 | 276,625 | |
| $23.87 | +0.31 | +1.3% | $23.56 | $24.55 | $23.34 | 231,128 | |
| $23.56 | +0.21 | +0.9% | $23.59 | $23.93 | $22.83 | 197,000 | |
| $23.35 | +0.02 | +0.1% | $22.98 | $23.99 | $22.36 | 230,000 | |
| $23.33 | +2.42 | +11.6% | $21.44 | $23.74 | $21.00 | 362,800 | |
| $20.91 | +1.83 | +9.6% | $19.13 | $20.91 | $19.06 | 217,900 | |
| $19.08 | +0.12 | +0.6% | $18.85 | $19.32 | $18.51 | 102,600 | |
| $18.96 | -0.27 | -1.4% | $20.30 | $20.30 | $18.87 | 106,700 | |
| $19.23 | -0.31 | -1.6% | $19.78 | $20.01 | $19.05 | 144,200 | |
| $19.54 | +0.13 | +0.7% | $19.68 | $19.74 | $19.34 | 78,900 | |
| $19.41 | +0.535 | +2.8% | $19.09 | $19.75 | $18.62 | 166,242 | |
| $18.88 | -0.075 | -0.4% | $18.68 | $18.90 | $18.30 | 137,149 | |
| $18.95 | +0.12 | +0.6% | $19.16 | $19.46 | $18.31 | 172,000 | |
| $18.83 | -0.43 | -2.2% | $19.22 | $19.99 | $18.40 | 210,600 | |
| $19.26 | -0.84 | -4.2% | $21.09 | $21.09 | $19.15 | 219,900 | |
| $20.10 | -1.50 | -6.9% | $19.26 | $21.12 | $17.89 | 592,200 | |
| $21.60 | +0.08 | +0.4% | $21.57 | $22.87 | $21.50 | 204,600 |
- Ticker
- NASDAQ:NVCT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 2, 2026
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 24 slides
Calls
Upcoming
Nuvectis Pharma (NASDAQ:NVCT) Q3 2026 Earnings Call
Wed, Nov 04, 2026 · 8:00 AM ET
Register
Latest news
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
Oct 26, 2026
Closed $18.49 (-7.8%) on Oct 26, 2026
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
Oct 9, 2026
Closed $21.12 (+4.9%) on Oct 9, 2026
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Sep 24, 2026
Closed $21.63 (+2.7%) on Sep 24, 2026
Nuvectis Pharma To Participate in Upcoming Investor Conferences
Sep 3, 2026
Closed $24.37 (+1.9%) on Sep 3, 2026
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
Aug 4, 2026
Closed $20.10 (-6.9%) on Aug 4, 2026
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Jul 23, 2026
Closed $20.15 (+4.5%) on Jul 23, 2026
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
Jun 29, 2026
Closed $18.39 (-35.5%) on Jun 30, 2026
Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
Jun 22, 2026
Closed $16.53 (+19.6%) on Jun 22, 2026
Financings
Public offering of shares (follow-on public offering)
Aug 4, 2026
Closed: US$115M raised
Use of proceeds: Advance development of NXP100 in PNH and other complement-mediated diseases and the oncology portfolio
Decks
Investor Presentation (October 2026)
Investor deck · 24 slides · October 2026
Investor Presentation (April 2023)
Investor deck · 23 slides · April 2023
Investor Presentation (November 2022)
Investor deck · 27 slides · November 2022
IPO Roadshow (January 2022)
IPO roadshow · 22 slides · Jan 18, 2022
Nuvectis Pharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 94 in all · newest Nov 2, 2026 · oldest 2022
- Decks
- 6 decks · latest October 2026
Where Nuvectis Pharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NVCT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:NVCT | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Nuvectis Pharma, Inc.